Literature DB >> 26041287

H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.

Manoj K Tripathy1, Mary E M McManamy1, Brandon D Burch1, Nancie M Archin1, David M Margolis2.   

Abstract

UNLABELLED: Histone methyltransferase inhibitors (HMTis) and histone deacetylase inhibitors (HDACis) are reported to synergistically induce the expression of latent human immunodeficiency virus type 1 (HIV-1), but studies have largely been performed with cell lines. As specific and potent HMTis directed at EZH1 (enhancer of zeste 2 Polycomb repressive complex 2 subunit 1)/EZH2 are now in human testing, we wished to rigorously test such an inhibitor in a primary resting T-cell model of HIV latency. We found that GSK343, a potent and selective EZH2/EZH1 inhibitor, reduced trimethylation of histone 3 at lysine 27 (H3K27) of the HIV provirus in resting cells. Remarkably, this epigenetic change was not associated with increased proviral expression in latently infected resting cells. However, following the reduction in H3K27 at the HIV long terminal repeat (LTR), subsequent exposure to the HDACi suberoylanilide hydroxamic acid or vorinostat (VOR) resulted in increases in HIV gag RNA and HIV p24 antigen production that were up to 2.5-fold greater than those induced by VOR alone. Therefore, in primary resting CD4(+) T cells, true mechanistic synergy in the reversal of HIV latency may be achieved by the combination of HMTis and HDACis. Although other cellular effects of EZH2 inhibition may contribute to the sensitization of the HIV LTR to subsequent exposure to VOR, and to increase viral antigen production, this synergistic effect is directly associated with H3K27 demethylation at nucleosome 1 (Nuc-1). Based upon our findings, the combination of HMTis and HDACis should be considered for testing in animal models or clinical trials. IMPORTANCE: Demethylation of H3K27 mediated by the histone methyltransferase inhibitor GSK343 in primary resting T cells is slow, occurring over 96 h, but by itself does not result in a significant upregulation of cell-associated HIV RNA expression or viral antigen production. However, following H3K27 demethylation, latent viral expression within infected primary resting CD4(+) T cells is synergistically increased upon exposure to the histone deacetylase inhibitor vorinostat. Demethylation at H3K27 sensitizes the HIV promoter to the effects of an HDACi and provides a proof-of-concept for the testing of combination epigenetic approaches to disrupt latent HIV infection, a necessary step toward the eradication of HIV infection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26041287      PMCID: PMC4524215          DOI: 10.1128/JVI.00572-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency.

Authors:  Young Kyeung Kim; Cyril F Bourgeois; Richard Pearson; Mudit Tyagi; Michelle J West; Julian Wong; Shwu-Yuan Wu; Cheng-Ming Chiang; Jonathan Karn
Journal:  EMBO J       Date:  2006-07-27       Impact factor: 11.598

Review 2.  Epigenetic regulation of HIV latency.

Authors:  Shweta Hakre; Leonard Chavez; Kotaro Shirakawa; Eric Verdin
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

3.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

4.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.

Authors:  Shay Matalon; Brent E Palmer; Marcel F Nold; Antonio Furlan; Afework Kassu; Gianluca Fossati; Paolo Mascagni; Charles A Dinarello
Journal:  J Acquir Immune Defic Syndr       Date:  2010-05-01       Impact factor: 3.731

6.  Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.

Authors:  Nancie M Archin; Kara S Keedy; Amy Espeseth; Herbert Dang; Daria J Hazuda; David M Margolis
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

7.  Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.

Authors:  Leonard C Edelstein; Sophia Micheva-Viteva; Bradley D Phelan; Joseph P Dougherty
Journal:  AIDS Res Hum Retroviruses       Date:  2009-09       Impact factor: 2.205

8.  Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein.

Authors:  Koen Bartholomeeusen; Yanhui Xiang; Koh Fujinaga; B Matija Peterlin
Journal:  J Biol Chem       Date:  2012-09-05       Impact factor: 5.157

9.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

Authors:  E Verdin; P Paras; C Van Lint
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

10.  Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Authors:  Datsen George Wei; Vicki Chiang; Elizabeth Fyne; Mini Balakrishnan; Tiffany Barnes; Michael Graupe; Joseph Hesselgesser; Alivelu Irrinki; Jeffrey P Murry; George Stepan; Kirsten M Stray; Angela Tsai; Helen Yu; Jonathan Spindler; Mary Kearney; Celsa A Spina; Deborah McMahon; Jacob Lalezari; Derek Sloan; John Mellors; Romas Geleziunas; Tomas Cihlar
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

View more
  39 in total

Review 1.  Underlying mechanisms of HIV-1 latency.

Authors:  Bizhan Romani; Elham Allahbakhshi
Journal:  Virus Genes       Date:  2017-03-03       Impact factor: 2.332

Review 2.  Host Methyltransferases and Demethylases: Potential New Epigenetic Targets for HIV Cure Strategies and Beyond.

Authors:  Daniela Boehm; Melanie Ott
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11       Impact factor: 2.205

3.  The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes.

Authors:  Ryan J Conrad; Parinaz Fozouni; Sean Thomas; Hendrik Sy; Qiang Zhang; Ming-Ming Zhou; Melanie Ott
Journal:  Mol Cell       Date:  2017-08-24       Impact factor: 17.970

4.  Tat expression led to increased histone 3 tri-methylation at lysine 27 and contributed to HIV latency in astrocytes through regulation of MeCP2 and Ezh2 expression.

Authors:  Ying Liu; Yinghua Niu; Lu Li; Khalid A Timani; Victor L He; Chris Sanburns; Jiafeng Xie; Johnny J He
Journal:  J Neurovirol       Date:  2019-04-24       Impact factor: 2.643

Review 5.  Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.

Authors:  David M Margolis; Nancie M Archin
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

Review 6.  Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection.

Authors:  Guido Ferrari; Barton F Haynes; Scott Koenig; Jeffrey L Nordstrom; David M Margolis; Georgia D Tomaras
Journal:  Nat Rev Drug Discov       Date:  2016-10-07       Impact factor: 84.694

7.  CBX4 contributes to HIV-1 latency by forming phase-separated nuclear bodies and SUMOylating EZH2.

Authors:  Liyang Wu; Ting Pan; Mo Zhou; Tao Chen; Shiyu Wu; Xi Lv; Jun Liu; Fei Yu; Yuanjun Guan; Bingfeng Liu; Wanying Zhang; Xiaohui Deng; Qianyu Chen; Anqi Liang; Yingtong Lin; Lilin Wang; Xiaoping Tang; Weiping Cai; Linghua Li; Xin He; Hui Zhang; Xiancai Ma
Journal:  EMBO Rep       Date:  2022-06-01       Impact factor: 9.071

8.  Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency.

Authors:  Todd Bradley; Guido Ferrari; Barton F Haynes; David M Margolis; Edward P Browne
Journal:  Cell Rep       Date:  2018-10-02       Impact factor: 9.423

Review 9.  Latency reversal and viral clearance to cure HIV-1.

Authors:  David M Margolis; J Victor Garcia; Daria J Hazuda; Barton F Haynes
Journal:  Science       Date:  2016-07-22       Impact factor: 47.728

10.  Histone H2A monoubiquitylation and p38-MAPKs regulate immediate-early gene-like reactivation of latent retrovirus HTLV-1.

Authors:  Anurag Kulkarni; Graham P Taylor; Robert J Klose; Christopher J Schofield; Charles Rm Bangham
Journal:  JCI Insight       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.